Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 166,011 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 166,011 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29. Following the sale, the insider now owns 11,150,461 shares of the company’s stock, valued at approximately $283,110,204.79. This represents a 1.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total value of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Stock Up 7.7 %

NAMS opened at $26.61 on Wednesday. NewAmsterdam Pharma has a twelve month low of $10.12 and a twelve month high of $27.29. The company has a 50-day simple moving average of $20.84 and a 200 day simple moving average of $18.81.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Banque Cantonale Vaudoise bought a new position in NewAmsterdam Pharma in the second quarter valued at approximately $38,000. Quarry LP lifted its stake in NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC boosted its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG bought a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at $128,000. Finally, XTX Topco Ltd acquired a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth $187,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on NAMS shares. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Scotiabank increased their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $36.20.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.